Radioactive 'Seeker' drug targets advanced cancers in first human test
NCT ID NCT06305962
Summary
This is a very early, first-in-human study to test the safety and find the right dose of a new radioactive drug called 177Lu-RAD204. It is for adults with advanced solid tumors (like lung, breast, or skin cancer) that have spread and have stopped responding to standard treatments. The drug is designed to seek out and deliver radiation directly to cancer cells that have a specific marker (PD-L1).
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Research SA (CRSA)
RECRUITINGAdelaide, South Australia, 5000, Australia
Contact Email: •••••@•••••
-
GenesisCare Murdoch
RECRUITINGMurdoch, Western Australia, 6150, Australia
Contact Email: •••••@•••••
-
Gold Coast University Hospital
RECRUITINGSouthport, Queensland, 4215, Australia
Contact Email: •••••@•••••
-
Nepean Hospital
RECRUITINGKingswood, New South Wales, 2747, Australia
Contact Email: •••••@•••••
-
Wollongong Hospital
RECRUITINGWollongong, New South Wales, 2500, Australia
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.